# Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.

> **NCT04704453** · PHASE2 · COMPLETED · sponsor: **Institut Claudius Regaud** · enrollment: 13 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Capsaïcin patch (Qutenza®)
- **DRUG:** Amitriptyline (Laroxyl®)

## Key facts

- **NCT ID:** NCT04704453
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-28
- **Primary completion:** 2025-04-28
- **Final completion:** 2025-04-28
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04704453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04704453, "Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04704453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*